What is Mallinckrodt Financial Strength?
Mallinckrodt has the Financial Strength Rank of 4.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Mallinckrodt did not have earnings to cover the interest expense.
Mallinckrodt's debt to revenue ratio for the quarter that ended in Sep. 2023 was 0.19.
As of today, Mallinckrodt's Altman Z-Score is -1.61.
Competitive Comparison of Mallinckrodt's Financial Strength
For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mallinckrodt's Financial Strength Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Financial Strength distribution charts can be found below:
* The bar in red indicates where Mallinckrodt's Financial Strength falls into.
Mallinckrodt Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Mallinckrodt's Interest Expense for the
months ended in Sep. 2023 was $-133 Mil. Its Operating Income for the
months ended in Sep. 2023 was $-4 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0 Mil.
Mallinckrodt's Interest Coverage for the quarter that ended in Sep. 2023 is
| Mallinckrodt did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Mallinckrodt's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Mallinckrodt has a Z-score of -1.61, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -1.61 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mallinckrodt (Mallinckrodt) Business Description
Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
| Alta Fundamental Advisers Llc |
10 percent owner |
1500 BROADWAY, SUITE 704, NEW YORK NY 10036 |
| Jason Daniel Goodson |
officer: EVP & Head of Corp Development |
106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885 |
| James R Sulat |
director |
|
| Paul Bisaro |
director |
|
| Sigurdur O Olafsson |
director, officer: President and CEO |
360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960 |
| Stephen Andrew Welch |
officer: EVP & Head of Spec Generics |
18440 BRIDGEMORE LANE, LOUISVILLE KY 40245 |
| Peter C Richardson |
officer: EVP & Chief Scientific Officer |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
| Susan Michele Silbermann |
director |
C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540 |
| Lisa French |
officer: EVP & Chief Commercial Officer |
301 CONTINENTAL LANE, PAOLI PA 19301 |
| Mark Anthony Tyndall |
officer: EVP & Chief Legal Offi & Secre |
1101 Q ST NW, WASHINGTON DC 20009 |
| Henriette Nielsen |
officer: EVP & Chief Transformation OFC |
202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024 |
| Karen Ling |
director |
C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
| Anne Clem Whitaker |
director |
109 BRIERY BRANCH COURT, MORRISVILLE NC 27560 |
| Olifant Luxco S.a R.l. |
10 percent owner |
19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273 |
| Paul Rutherford Carter |
director |
SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCKPF has been successfully added to your